{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:41:21Z","timestamp":1790260881302,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.humpath.2016.01.010","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T17:15:40Z","timestamp":1454692540000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas"],"prefix":"10.1016","volume":"52","author":[{"given":"Christelle","family":"Combaz-Lair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Galateau-Sall\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"McLeer-Florin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolwenn","family":"Le Stang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"David-Boudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Duruisseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert R.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Lebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lantuejoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.01.010_bb0005","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"10.1016\/j.humpath.2016.01.010_bb0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ijc.24711","article-title":"Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005","volume":"126","author":"Le Stang","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2016.01.010_bb0015","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1684\/bdc.2013.1857","article-title":"Malignant pleural mesothelioma: 2013 state of the art","volume":"100","author":"Campbell","year":"2013","journal-title":"Bull Cancer"},{"key":"10.1016\/j.humpath.2016.01.010_bb0020","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1634\/theoncologist.2014-0122","article-title":"Current issues in malignant pleural mesothelioma evaluation and management","volume":"19","author":"Ai","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.humpath.2016.01.010_bb0025","series-title":"Tumours of the pleura. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2004"},{"key":"10.1016\/j.humpath.2016.01.010_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.humpath.2016.01.010_bb0035","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.01.010_bb0040","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.01.010_bb0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.humpath.2016.01.010_bb0050","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.humpath.2016.01.010_bb0055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm0902-1039c","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2016.01.010_bb0060","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2016.01.010_bb0065","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, bms-936558, ono-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2016.01.010_bb0070","series-title":"Intech Oncogene and Cancer - From Bench to Clinic: CC BY 3.0 license","article-title":"Dual role of tlr3 in inflammation and cancer cell apoptosis","author":"Estornes","year":"2013"},{"key":"10.1016\/j.humpath.2016.01.010_bb0075","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2016.01.010_bb0080","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.4049\/jimmunol.176.8.4894","article-title":"TLR3 can directly trigger apoptosis in human cancer cells","volume":"176","author":"Salaun","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.humpath.2016.01.010_bb0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.onc.1210906","article-title":"Toll-like receptors and immune regulation: implications for cancer therapy","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2016.01.010_bb0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/CMR.00022-07","article-title":"Sensing of viral infection and activation of innate immunity by toll-like receptor 3","volume":"21","author":"Vercammen","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.humpath.2016.01.010_bb0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1158\/0008-5472.CAN-10-3490","article-title":"TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer","volume":"71","author":"Salaun","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.01.010_bb0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00262-010-0931-0","article-title":"Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence","volume":"60","author":"Gonz\u00e1lez-Reyes","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"1 Suppl.","key":"10.1016\/j.humpath.2016.01.010_bb0105","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1111\/j.1365-2567.2008.03041.x","article-title":"Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas","volume":"128","author":"Rydberg","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.humpath.2016.01.010_bb0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2015.02.027","article-title":"TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells","volume":"361","author":"Boes","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2016.01.010_bb0115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2016.01.010_bb0120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"de Perrot","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2016.01.010_bb0125","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.humpath.2016.01.010_bb0130","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (pd-l1) in malignant pleural mesothelioma (mpm)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2016.01.010_bb0135","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2016.01.010_bb0140","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PDL1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Schultheis","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2016.01.010_bb0145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/JTO.0b013e318292be18","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)","volume":"8","author":"Velcheti","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2016.01.010_bb0150","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.01.010_bb0155","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"pd-l1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2016.01.010_bb0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non\u2013small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.humpath.2016.01.010_bb0165","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","article-title":"Clinical impact of programmed cell death ligand 1 expression in colorectal cancer","volume":"49","author":"Droeser","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2016.01.010_bb0170","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with longterm follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.01.010_bb0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Wu","year":"2006","journal-title":"Acta Histochem"},{"key":"10.1016\/j.humpath.2016.01.010_bb0180","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2016.01.010_bb0185","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1158\/1078-0432.CCR-09-1438","article-title":"Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype","volume":"15","author":"Ogino","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.01.010_bb0190","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/PPO.0b013e3181eaca65","article-title":"Toll-like receptor agonists: are they good adjuvants?","volume":"16","author":"Gnjatic","year":"2010","journal-title":"Cancer J"},{"key":"10.1016\/j.humpath.2016.01.010_bb0195","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/onci.20696","article-title":"Trial Watch: Experimental Toll-like receptor agonists for cancer therapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunology"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716000423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716000423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T09:15:46Z","timestamp":1567588546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":39,"alternative-id":["S0046817716000423"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.01.010","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}